PDF
ePub
Citation
Print
Abstract
Purpose
Osteopontin (OPN) is one of the major non-collagenous bone matrix proteins produced by osteoblasts and osteolclasts, and it is also involved in the pathogenesis of urolithiasis. Single nucleotide polymor-phisms (SNPs), as a tool for searching for the genetic markers of disease, have a large role in investigating the genetic markers of complex human diseases. The aim of this study is to investigate the association with this SNP at position nucleotide 9250 (C→T) in the OPN gene and the susceptibility to urolithiasis. We also compared the allele frequency of Koreans with those of Americans and Japanese.
Materials and Methods
A total of 161 urolithiasis patients and 104 healthy controls were studied. The SNPs located at position 9520 in the OPN gene were genotyped using restriction fragment length polymorphism (RFLP). The wild-type sequence contains a C while the polymorphism variant is a T (C→T), which results in the appearance of an Alu I restriction site.
Results
The gene frequencies of C/C, C/T and T/T at position 9250 on the Eta-1/osteopontin gene in urolithiasis patients were 10.6%, 36.6% and 52.8%, respectively, compared with 6.7%, 27.9% and 65.8%, respectively, in the controls (p＞0.05). The allele frequencies of C and T at this position in the urolithiasis patients were 28.9 and 72.1, respectively, whereas those in the controls were 20.7 and 79.3, respectively, (p＜0.05). The allele frequencies found in the present study were compared with those coding SNPs described in the USA database; 60 and 39 (USA) vs 20.7 and 79.3 (Korea), respectively (p＜0.05).
Conclusions
Those findings suggest there is no association of with Eta-1/osteopontin genetic polymorphism, but the allele frequencies were significantly associated with urolithiasis patients. We also observed difference of allele frequencies in our controls and in the USA controls and these differences may be caused by a difference in the incidence of urolithiasis patients between the two countries.
References
1. Leusmann DB, Blaschke R, Schmandt W. Results of 5,035 stone analysis: a contribution to epidemiology of urinary stone disease. Scand J Urol Nephrol. 1990; 24:205–10.
2. Watts RW. Idiopathic urinary stone disease: possible polygenic aetiological factors. QJM. 2005; 98:241–6.
3. Xie Y, Sakatsume M, Nishi S, Narita I, Arakawa M, Gejyo F. Expression, roles, receptors, and regulation of osteopontin in the kidney. Kidney Int. 2001; 60:1645–57.
4. Forton AC, Petri MA, Goldman D, Sullivan KE. An osteopontin (SPP1) polymorphism is associated with systemic lupus erythematosus. Hum Mutat. 2002; 19:459.
5. Gao B, Yasui T, Okada A, Tozawa K, Hayashi Y, Kohri K. A polymorphism of the osteopontin gene is related to urinary calcium stones. J Urol. 2005; 174:1472–6.
6. Lopez CA, Hoyer JR, Wilson PD, Waterhouse P, Denhardt DT. Heterogeneity of osteopontin expression among nephrons in mouse kidneys and enhanced expression in sclerotic glomeruli. Lab Invest. 1993; 69:355–63.
7. Noiri E, Dickman K, Miller F, Romanov G, Romanov VI, Shaw R, et al. Reduced tolerance to acute renal ischemia in mice with a targeted disruption of the osteopontin gene. Kidney Int. 1999; 56:74–82.
8. Asplin JR, Arsenault D, Parks JH, Coe FL, Hoyer JR. Contribution of human uropontin to inhibition of calcium oxalate crystallization. Kidney Int. 1998; 53:194–9.
9. Lieske JC, Leonard R, Toback FG. Adhesion of calcium oxalate monohydrate crystals to renal epithelial cells is inhibited by specific anions. Am J Physiol. 1995; 268:F604–12.
10. Worcester EM, Beshensky AM. Osteopontin inhibits nucleation of calcium oxalate crystals. Ann NY Acad Sci. 1995; 760:375–7.
11. Wesson JA, Worcester EM, Wiessner JH, Mandel NS, Kleinman JG. Control of calcium oxalate crystal structure and cell adherence by urinary macromolecules. Kidney Int. 1998; 53:952–7.
12. Yamate T, Kohri K, Umekawa T, Amasaki N, Amasaki N, Isikawa Y, et al. The effect of osteopontin on the adhesion of calcium oxalate crystals to Madin-Darby canine kidney cells. Eur Urol. 1996; 30:388–93.
13. de Water R, Boeve ER, van Miert PP, Vermaire CP, van Run PR, Cao LC, et al. Pathological and immunocytochemical changes in chronic calcium oxalate nephrolithiasis in the rat. Scanning Microsc. 1996; 10:577–87.
14. de Water R, Leenen PJ, Noordermeer C, Nigg AL, Houts-muller AB, Kok DJ, et al. Cytokine production induced by binding and processing of calcium oxalate crystals in cultured macrophages. Am J Kidney Dis. 2001; 38:331–8.
15. Kim H, Jo MK, Kwak C, Park SK, Yoo KY, Kang D, et al. Prevalence and epidemiologic characteristics of urolithiasis in Seoul, Korea. Urology. 2002; 59:517–21.
16. Curhan GC, Rimm EB, Willett WC, Stampfer MJ. Regional variation in nephrolithiasis incidence and prevalence among United States men. J Urol. 1994; 151:838–41.
17. Iwasaki H, Shinohara Y, Ezura Y, Ishida R, Kodaira M, Kajita M, et al. Thirteen single-nucleotide polymorphisms in the human osteopontin gene identified by sequencing of the entire gene in Japanese individuals. J Hum Genet. 2001; 46:544–6.
18. Scheinman SJ. Nephrolithiasis. Semin Nephrol. 1999; 19:381–8.
Fig. 1.
Representative agarose gel electrophoresis illustrating the restriction fragment length polymorphism (PCR-RFLP) products for the Eta-1/osteopontin gene polymorphism. The nt 9250 polymorphism in exon 7: lane 1, homozygous T/T subject; lane 2, heterozygous C/T subject; lane 3, homozygous C/C subject. C allele cut with Alu I, which generated 147- and 105-bp fragments and the T allele cut with Alu I generated 61- and 44-bp fragments.
Table 1.
Gene and allele frequencies at nt 9250 of the Eta-1/ost opontin gene in the urolithiasis patients and the healthy contro
Table 2.
Laboratory findings in urolithiasis patients according to the gene variation at nucleotide 9250 on the Eta-1/osteopontin gene
XML Download